Global Monoclonal Antibodies (mAbs) Biosimilars Market Strategic Research Report

Scope of the Report

The global Monoclonal Antibodies (mAbs) Biosimilars market size is predicted to grow from US$ 14,625 million in 2025 to US$ 47,680 million in 2032; it is expected to grow at a CAGR of 17.8% from 2026 to 2032.

Monoclonal antibody (mAb) biosimilars are highly similar, lower-cost versions of approved, brand-name biological drugs used to treat cancers, autoimmune diseases, and infections. They are developed after a reference mAb's patent expires and are proven to have no clinically meaningful differences in efficacy, safety, or quality compared to the original, providing greater patient access to advanced therapies.

The global supply structure has become increasingly multi-polar. SouthKorean companies such as Celltrion and SamsungBioepis have built broad, globally visible portfolios across immunology, oncology, ophthalmology and hematology. Large western pharmaceutical and generic groups such as Amgen, Pfizer, Sandoz, FreseniusKabi, Organon and BoehringerIngelheim compete through regulatory scale, commercialization networks and established healthcare-system access. Indian companies such as BioconBiologics, Dr.Reddy’s, Intas/Accord and Lupin combine cost-competitive development with growing regulated-market ambitions. Chinese companies such as Henlius, Bio-Thera, Qilu and Innovent are moving from domestic approvals toward international filings and licensing partnerships. The market is also shaped by partnership models, such as Alvotech/Teva, Formycon/FreseniusKabi, Bio-Thera/STADA and Bio-Thera/GedeonRichter, where one party often leads development and manufacturing while another leads regional commercialization.

Demand growth is being driven by the expansion of biosimilar competition into high-spend reference biologics. The first major wave centered on oncology and immunology products such as trastuzumab, bevacizumab, rituximab, infliximab and adalimumab. The next wave is expanding into ustekinumab, tocilizumab, ranibizumab, aflibercept, denosumab, eculizumab, omalizumab and other antibody-related products. However, regulatory approval alone does not guarantee rapid uptake. The ASPE report on U.S. biosimilar market entry highlights that market size and entry order affect biosimilar revenues, and that markets such as bevacizumab, rituximab and trastuzumab took time to reach peak biosimilar share. In practice, adoption depends on payer policy, tendering rules, formulary access, physician confidence, patient switching, interchangeability status, originator contracting and supply reliability.

From a product and strategy perspective, the market is moving beyond simple “first biosimilar to a blockbuster mAb” competition. Future differentiation will increasingly depend on high-concentration formulations, citrate-free presentations, prefilled syringes, autoinjectors, interchangeability designations, global dossier reuse, real-world evidence, manufacturing cost control and broad market-access execution. The U.S. and Europe will remain the most valuable regulated markets, but China, India, Latin America, the Middle East and Southeast Asia are increasingly important for volume growth and regional commercialization partnerships. The long-term outlook is positive because many high-value biologics are entering or approaching biosimilar competition, but price erosion can be severe once multiple entrants compete. Companies with integrated R&D, manufacturing, regulatory and commercialization capabilities are therefore better positioned than firms that rely only on low-cost production or single-market approvals.

This report presents a comprehensive overview of the global Monoclonal Antibodies (mAbs) Biosimilars market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Adalimumab Biosimilars
• Infliximab Biosimilars
• Rituximab Biosimilars
• Trastuzumab Biosimilars
• Bevacizumab Biosimilars
• Ranibizumab Biosimilars
• Ustekinumab Biosimilars
• Tocilizumab Biosimilars
• Denosumab Biosimilars
• Other mAb Biosimilars

Segment by Dosage Form

• Intravenous Infusion Vials
• Subcutaneous Prefilled Syringes
• Autoinjectors
• Lyophilized Powder for Injection
• Concentrate for Solution for Infusion
• Ophthalmic Intravitreal Injection
• Multiple Presentations

Segment by Molecular Target

• TNF-α Inhibitors
• CD20-targeting Antibodies
• HER2-targeting Antibodies
• VEGF/VEGF-A Inhibitors
• IL-6R Inhibitors
• IL-12/23 Inhibitors
• RANKL Inhibitors
• C5 Complement Inhibitors
• IgE Inhibitors
• Other Targets

Segment by Application

• Oncology
• Autoimmune and Inflammatory Diseases
• Ophthalmology
• Bone Disease and Osteoporosis
• Hematology and Rare Diseases
• Asthma and Allergy
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Monoclonal Antibodies (mAbs) Biosimilars market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Oncology, Autoimmune and Inflammatory Diseases, Ophthalmology evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact